140 related articles for article (PubMed ID: 20557439)
1. Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity.
Huang RA; Letendre LT; Banav N; Fischer J; Somerville B
J Vet Pharmacol Ther; 2010 Jun; 33(3):227-37. PubMed ID: 20557439
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary epithelial lining fluid in naturally occurring bovine respiratory disease in multisource commingled feedlot cattle.
DeDonder KD; Apley MD; Li M; Gehring R; Harhay DM; Lubbers BV; White BJ; Capik SF; KuKanich B; Riviere JE; Tessman RK
J Vet Pharmacol Ther; 2016 Apr; 39(2):157-66. PubMed ID: 26441021
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in broiler chickens.
Watteyn A; Plessers E; Wyns H; De Baere S; De Backer P; Croubels S
Poult Sci; 2013 Jun; 92(6):1516-22. PubMed ID: 23687147
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs.
Wyns H; Meyer E; Plessers E; Watteyn A; De Baere S; De Backer P; Croubels S
Res Vet Sci; 2014 Feb; 96(1):160-3. PubMed ID: 24331716
[TBL] [Abstract][Full Text] [Related]
5. Gamithromycin plasma and skin pharmacokinetics in sheep.
Kellermann M; Huang RA; Forbes AB; Rehbein S
Res Vet Sci; 2014 Oct; 97(2):199-203. PubMed ID: 25241389
[TBL] [Abstract][Full Text] [Related]
6. Gamithromycin in swine: Pharmacokinetics and clinical evaluation against swine respiratory disease.
Hamel D; Richard-Mazet A; Voisin F; Böhne I; Fraisse F; Rauh R; Huang R; Kellermann M; Letendre L; Dumont P; Rehbein S
Vet Med Sci; 2021 Mar; 7(2):455-464. PubMed ID: 33058489
[TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetics, pulmonary distribution, and in vitro activity of gamithromycin in foals.
Berghaus LJ; Giguère S; Sturgill TL; Bade D; Malinski TJ; Huang R
J Vet Pharmacol Ther; 2012 Feb; 35(1):59-66. PubMed ID: 21443748
[TBL] [Abstract][Full Text] [Related]
8. Determination of the duration of antibacterial efficacy following administration of gamithromycin using a bovine Mannheimia haemolytica challenge model.
Forbes AB; Ramage C; Sales J; Baggott D; Donachie W
Antimicrob Agents Chemother; 2011 Feb; 55(2):831-5. PubMed ID: 21078926
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis.
Wei XY; Zhang J; Zhang Y; Fu WZ; Zhong LG; Pan YD; Sun J; Liao XP; Liu YH; Zhou YF
BMC Vet Res; 2024 Apr; 20(1):147. PubMed ID: 38643185
[TBL] [Abstract][Full Text] [Related]
10. Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves.
ismail M
Vet Res Commun; 2007 May; 31(4):467-76. PubMed ID: 17216308
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets.
Zhou YF; Bu MX; Liu P; Sun J; Liu YH; Liao XP
BMC Vet Res; 2020 Mar; 16(1):81. PubMed ID: 32138735
[TBL] [Abstract][Full Text] [Related]
12. Disposition of gamithromycin in plasma, pulmonary epithelial lining fluid, bronchoalveolar cells, and lung tissue in cattle.
Giguère S; Huang R; Malinski TJ; Dorr PM; Tessman RK; Somerville BA
Am J Vet Res; 2011 Mar; 72(3):326-30. PubMed ID: 21355734
[TBL] [Abstract][Full Text] [Related]
13. Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foals.
Berlin S; Wallstabe S; Scheuch E; Oswald S; Hasan M; Wegner D; Grube M; Venner M; Ullrich A; Siegmund W
Equine Vet J; 2018 Jul; 50(4):525-531. PubMed ID: 29239016
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate.
Aliabadi FS; Lees P
J Vet Pharmacol Ther; 2002 Jun; 25(3):161-74. PubMed ID: 12081611
[TBL] [Abstract][Full Text] [Related]
15. Synovial fluid pharmacokinetics of tulathromycin, gamithromycin and florfenicol after a single subcutaneous dose in cattle.
Jones ML; Washburn KE; Fajt VR; Rice S; Coetzee JF
BMC Vet Res; 2015 Feb; 11():26. PubMed ID: 25886555
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of gamithromycin in turkey poults with respect to Ornithobacterium rhinotracheale.
Watteyn A; Devreese M; De Baere S; Wyns H; Plessers E; Boyen F; Haesebrouck F; De Backer P; Croubels S
Poult Sci; 2015 Sep; 94(9):2066-74. PubMed ID: 26195808
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine.
Benchaoui HA; Nowakowski M; Sherington J; Rowan TG; Sunderland SJ
J Vet Pharmacol Ther; 2004 Aug; 27(4):203-10. PubMed ID: 15305848
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle).
Menge M; Rose M; Bohland C; Zschiesche E; Kilp S; Metz W; Allan M; Röpke R; Nürnberger M
J Vet Pharmacol Ther; 2012 Dec; 35(6):550-9. PubMed ID: 22188102
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of the metaphylactic use of gamithromycin against bacterial pathogens associated with bovine respiratory disease in a multicentre farm trial.
Baggott D; Casartelli A; Fraisse F; Manavella C; Marteau R; Rehbein S; Wiedemann M; Yoon S
Vet Rec; 2011 Mar; 168(9):241. PubMed ID: 21493573
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle.
Elias G; Lee JS; Hwang MH; Park YS; Cho KH; Kim YH; Park SC
J Vet Pharmacol Ther; 2009 Jun; 32(3):219-28. PubMed ID: 19646085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
